Topical Boswellia Serrata 2% to Prevent Radiation Dermatitis in Head and Neck Cancer

Inclusion Criteria: \- Inclusion Criteria: * Adults aged 18 years or older, of any sex, with histologically confirmed head and neck cancer for which radiotherapy is indicated * Planned external-beam radiotherapy to the head and neck region (curative or adjuvant intent) with a planned total dose of at least 60 Gy; concurrent chemotherapy is permitted * Able to provide written informed consent and comply with the protocol (twice-daily cream application, follow-up visits, and a skin diary) * Agreement to avoid other topical treatments in the radiation field during the study period (except study-provided or allowed rescue medication) Exclusion Criteria: * Previous radiotherapy to the same site * Previous extensive surgery or reconstruction in the head and neck region that substantially alters the radiation field or interferes with skin assessment * Known allergy or hypersensitivity to Boswellia serrata, boswellic acids, or any component of the cream base * Current use of systemic corticosteroids or anti-inflammatory medications that could influence skin reactions (low-dose corticosteroids as chemotherapy premedication are allowed) * Dermatologic conditions in the treatment area that could interfere with assessment (e.g., psoriasis, scleroderma, severe acne, chronic wounds) * Pre-existing dermatitis or significant skin lesions in the radiation field at baseline * Pregnancy or breastfeeding * Any other condition that, in the investigator's judgment, would compromise participation or confound the results Exclusion Criteria: \-